FDA Adds Eye Warning to Ozempic, Wegovy, Mounjaro and Zepbound: What to Watch For

FDA Adds Eye Warning to Ozempic, Wegovy, Mounjaro and Zepbound: What to Watch For

Direct answer: On November 9, 2026, the U.S. Food and Drug Administration (FDA) required all GLP-1 medicines — including Ozempic, Wegovy, Mounjaro, and Zepbound — to add a warning about a potential increased risk of NAION, a rare eye condition that can cause sudden, painless vision loss in one eye, including permanent vision loss. In the FDA's review of 126 clinical trials covering 134,253 patients, 15 probable NAION cases appeared: 10 in people taking a GLP-1 drug and 5 in people taking a placebo. The rate was 6.4 cases per 100,000 person-years with a GLP-1 drug, compared with 3.8 per 100,000 person-years in comparison groups, according to the FDA, November 9, 2026.

What is NAION?

NAION stands for non-arteritic anterior ischemic optic neuropathy. It happens when blood flow to the front part of the optic nerve drops. The result is sudden, painless vision loss in one eye, sometimes in both eyes.

Vision loss from NAION is often noticed on waking. Other signs include blurred or missing areas of vision, color distortion, and reduced central sharpness, according to the FDA communication. The condition can lead to permanent vision loss. Its underlying cause is not completely understood, according to the FDA.

Risk factors the FDA lists for NAION include smoking, diabetes, high blood pressure, sleep apnea, anemia, and kidney disease. These conditions often overlap with the reasons people take GLP-1 medicines in the first place.

Which medicines are affected?

The warning applies to the whole GLP-1 receptor agonist class, not to one brand. NAION cases have been reported for all currently marketed GLP-1 RA products, according to the FDA, November 9, 2026.

The medicines include semaglutide (Ozempic, Rybelsus, Wegovy), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), exenatide, lixisenatide combinations (Soliqua), liraglutide plus insulin degludec (Xultophy), and orforglipron (Foundayo), approved in 2026. These medicines are prescribed for type 2 diabetes, for weight management, or for both.

What did the FDA find?

The FDA began its review after a July 2024 study in JAMA Ophthalmology reported a link between semaglutide and NAION. The agency then reviewed clinical trial data, animal data, and postmarketing data, including observational studies and case reports.

The animal data did not identify a mechanism for how GLP-1 use could raise NAION risk, according to the FDA. The agency still concluded that the combined evidence supports a potential increased risk of rare NAION events in people taking GLP-1 medicines.

Group	Patients	Person-years	Probable NAION cases	Rate per 100,000 person-years
GLP-1 drug	78,217	156,947	10	6.4
Comparator (placebo or other diabetes drug)	56,036	131,932	5	3.8

The table above comes from the FDA meta-analysis of 126 randomized trials, published November 9, 2026. All 5 comparator cases were in people who received a placebo. No cases appeared in people who received another non-GLP-1 glucose-lowering medicine.

What did the FDA's real-world study show?

The FDA also ran a retrospective study using its Sentinel real-world data system. It covered adults with type 2 diabetes who started a GLP-1 drug, an SGLT-2 inhibitor, or a DPP-4 inhibitor between 2019 and 2024.

NAION rates in that study ranged from 26 to 32 events per 100,000 person-years: 30 to 32 for GLP-1 drugs, 31 for SGLT-2 inhibitors, and 26 for DPP-4 inhibitors. The risk increase was not statistically significant compared with SGLT-2 inhibitors (hazard ratio 1.19, 95% CI 0.91 to 1.54). Compared with DPP-4 inhibitors, the hazard ratio was 1.43 (95% CI 1.02 to 2.01), according to the FDA, November 9, 2026.

Published observational studies that the FDA reviewed also reported an increased NAION risk in people with type 2 diabetes who started a GLP-1 drug, compared with those who started a DPP-4 inhibitor or an SGLT-2 inhibitor. The FDA noted that no single data source settled the question on its own.

Is this a recall?

No. No GLP-1 product is being withdrawn, recalled, or restricted. The FDA is requiring only a labeling change: application holders must add NAION risk information to the Warnings and Precautions section of each product's labeling.

Europe moved earlier on the same concern. In 2025, the European Medicines Agency's safety committee said NAION may affect up to 1 in 10,000 people taking semaglutide, according to Reuters, November 9, 2026. Warnings about semaglutide and NAION were added to European labels for Wegovy and Ozempic in June 2025.

What should you do if you notice vision changes?

• Report sudden, painless vision loss, a visual field deficit, or any other visual change in one eye to your clinician right away.
• Ask for a prompt referral to an ophthalmologist if NAION is suspected. The FDA advises clinicians to refer patients with suspected NAION promptly to an eye specialist.
• Do not stop a prescribed GLP-1 medicine on your own. The FDA did not tell patients to stop these medicines.
• Bring a list of your medicines, including the brand name and dose, to the eye appointment.

Frequently asked questions

Does this warning mean GLP-1 drugs cause blindness?
No. The FDA concluded there is a potential increased risk of a rare condition, not proof that the drugs cause it. The agency found signals pointing to a possible association, but it did not determine whether GLP-1 drugs can cause NAION.

How rare is NAION with these medicines?
In the FDA's trial analysis, 15 probable cases appeared among 134,253 patients across 126 trials. The rate was 6.4 cases per 100,000 person-years with a GLP-1 drug, versus 3.8 per 100,000 person-years in comparison groups, according to the FDA, November 9, 2026.

Should I stop taking my GLP-1 medicine?
Do not stop a prescribed medicine without talking to your clinician. The FDA's action is a labeling change, not a stop-use order. Your clinician can weigh the vision warning against the medicine's benefits for your diabetes or weight.

What symptoms should I watch for?
Sudden, painless loss of vision in one eye, a missing area in your field of vision, blurred vision, color distortion, or reduced central sharpness. These changes are often noticed on waking. Report them immediately and ask for an ophthalmology referral.

Does the warning cover compounded GLP-1 products?
The FDA requirement applies to approved GLP-1 medicines and their labeling. Compounded products are not FDA-approved medicines, and they do not carry FDA-approved labeling. If you use a compounded product, ask your prescriber or pharmacist what applies to you.

Key Takeaway

The FDA's new warning covers every GLP-1 medicine, but NAION remains rare — 10 cases versus 5 in 126 trials. The one action that matters is speed: sudden, painless vision loss in one eye should be reported right away and checked by an eye specialist.

Sources: U.S. Food and Drug Administration, Drug Safety Communication, “FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition,” published November 9, 2026; Reuters, “US FDA orders new eye risk warnings for Ozempic, Zepbound,” November 9, 2026; USA Today, “FDA says popular GLP-1 drugs linked to rare risk of vision loss, blindness,” November 9, 2026.

---

This post was created with the help of AI tools and reviewed for accuracy against the sources cited above. It is general information only, not medical advice. For decisions about your own medicine, please talk to your doctor or pharmacist.

49,420 Bottles of a Common Antibiotic Recalled: Check These 6 Lots

49,420 Bottles of a Common Antibiotic Recalled: Check These 6 Lots

Direct answer: The U.S. Food and Drug Administration (FDA) classified a Class II recall of 49,420 bottles of the antibiotic ciprofloxacin on November 3, 2026, after tests found levels of a nitrosamine impurity above the FDA-recommended limit. Only six lots are affected — three lots of 500 mg tablets and three lots of 750 mg tablets, all expiring December 31, 2026. If your bottle matches one of those lots, contact your pharmacist to check — and do not stop a prescribed antibiotic on your own.

What was recalled?

The recall covers ciprofloxacin tablets made by Hikma Pharmaceuticals and distributed in the United States by Hikma Pharmaceuticals USA Inc. Ciprofloxacin is a prescription antibiotic used to treat a range of bacterial infections, including urinary tract infections, kidney infections, certain gastrointestinal infections, and some respiratory infections.

The FDA reason is listed as “N-nitroso-ciprofloxacin results above the FDA-recommended interim control limit.” The FDA classified the recall as Class II on November 3, 2026 (recall numbers D-0165-2027 and D-0166-2027). A Class II recall means use of the product may cause temporary or medically reversible health consequences, or that the probability of serious harm is remote, according to the FDA definition.

N-nitroso-ciprofloxacin is a type of nitrosamine, an impurity also found in water and some foods. The FDA sets limits on nitrosamines in medicines to help keep potential health risks low. Some nitrosamine impurities may increase cancer risk when people are exposed to levels above acceptable limits over long periods of time, though not all nitrosamines carry the same risk.

Which lots should you check?

Strength	Bottle size	Lot numbers	NDC	Bottles recalled	Expiration
500 mg	100 tablets	CB496A, CB497A, CB498A	0143-9928-01	29,085	Dec 31, 2026
750 mg	50 tablets	CA083A, CA084A, CA085A	0143-9929-50	20,335	Dec 31, 2026

The recalled bottles were distributed nationwide in the United States. Check three things on your bottle: the medicine name, the manufacturer (Hikma), and the lot number.

Is my bottle affected if it looks different?

Only the six lots above are in scope. If your bottle shows a different lot number, a different manufacturer, or a different strength or bottle size, it is not part of this recall listing. One practical catch: if your medicine was transferred into a plain pharmacy bottle, the manufacturer lot number may not appear on the label. In that case, call the pharmacy that filled the prescription and ask whether your medicine came from one of the recalled lots.

The recall is limited to the wholesale, distributor, and retail pharmacy levels, according to the notice published by the California State Board of Pharmacy. A medical assessment of the affected lots concluded that the observed N-nitroso-ciprofloxacin levels are “not expected to adversely impact patient safety.”

What should you do if your lot matches?

• Contact your pharmacist or prescribing clinician and ask what to do next.
• Ask whether to keep taking the medicine while a replacement is arranged.
• Follow any return or disposal instructions your pharmacy provides.
• Do not stop a prescribed antibiotic without first talking to your doctor or pharmacist — stopping an antibiotic early can carry its own risks, and the FDA notes that patients can generally continue using a medicine in a Class II recall unless the company or the agency directs otherwise.

How is this different from other recent recalls?

Not every recall means contamination. This one is about an impurity found above the FDA's interim limit, not a reported contamination finding, and not a tablet that fails to dissolve. It is also narrow: 49,420 bottles in six lots, rather than every bottle of this antibiotic on the market. That is why the lot number — not just the medicine name — is the deciding detail.

Frequently asked questions

Is all ciprofloxacin recalled?
No. The FDA listing covers only the six Hikma lots above. Other manufacturers' ciprofloxacin, and other Hikma lots, are not part of this recall.

Does a Class II recall mean the medicine is dangerous?
Class II is the FDA's middle severity tier. It means temporary or reversible health consequences are possible, while the probability of serious harm is remote. It is not a reason to change your routine without professional guidance.

What if I already took tablets from one of these lots?
Talk to your pharmacist or prescriber about it. The medical assessment published with the recall notice concluded the observed impurity levels are not expected to adversely impact patient safety. You can also report a medication-quality problem through the FDA MedWatch program or by calling 800-FDA-1088.

Where can I verify this myself?
Search the FDA Enforcement Reports for recall numbers D-0165-2027 and D-0166-2027, or check the lot number and NDC on your bottle against the table above.

Key Takeaway

Check the lot number, not just the medicine name: only six Hikma ciprofloxacin lots (49,420 bottles, expiring December 31, 2026) are recalled, and your pharmacist is the right first call if yours matches.

Sources: FDA Enforcement Report, Event 100142, recalls D-0165-2027 and D-0166-2027, Class II classified November 3, 2026; The Healthy, “FDA: Nearly 50,000 Bottles of Common Antibiotic Recalled Nationwide,” November 4, 2026; California State Board of Pharmacy recall notice, Hikma Pharmaceuticals USA Inc. ciprofloxacin tablets.

---

This post was created with the help of AI tools and reviewed for accuracy against the sources cited above. It is general information only, not medical advice. For decisions about your own medicine, please talk to your doctor or pharmacist.

 

Check Your Blood Pressure Bottle: 3,744 Bottles Recalled After Tablets Fail Dissolution Test

Check Your Blood Pressure Bottle: 3,744 Bottles Recalled After Tablets Fail Dissolution Test

Direct answer: The U.S. Food and Drug Administration (FDA) classified a Class II recall of 3,744 bottles of a generic three-in-one blood pressure tablet made for Macleods Pharma USA, after the tablets failed dissolution specifications. Only two lots are affected, both expiring May 31, 2027. If your bottle matches one of those lots, contact your pharmacist or prescriber for guidance — and do not stop a prescribed blood pressure medicine on your own.

What was recalled?

The recall covers olmesartan medoxomil, amlodipine, and hydrochlorothiazide tablets, 40 mg / 10 mg / 12.5 mg — a single tablet that combines three blood pressure medicines. It is a generic version of the brand-name drug Tribenzor. The FDA recall listing does not include brand-name Tribenzor.

The company, Macleods Pharma USA, voluntarily initiated the recall on October 7, 2026. The FDA classified it as Class II on October 26, 2026 (recall number D-0077-2027). A Class II recall means use of the product may cause temporary or medically reversible health consequences, or that the probability of serious harm is remote, according to the FDA definition.

The FDA reason is listed as “failed dissolution specifications.” In plain terms, the tablets did not break down and release their ingredients as required in laboratory quality testing, so they may not work as expected.

Which lots should you check?

30-tablet bottles: lot 12251163A, NDC 33342-246-07, 3,528 bottles, expires May 31, 2027. 90-tablet bottles: lot 12251163B, NDC 33342-246-10, 216 bottles, expires May 31, 2027. The recalled bottles were distributed nationwide in the United States. Check three things on your bottle: the medicine name, the manufacturer (Macleods), and the lot number.

Is my bottle affected if it looks different?

Only the two lots above are in scope. If your bottle shows a different lot number, a different manufacturer, or the brand-name product, it is not part of this recall listing. One practical catch: if your medicine was transferred into a plain pharmacy bottle, the manufacturer lot number may not appear on the label. In that case, call the pharmacy that filled the prescription and ask whether your medicine came from one of the recalled lots.

What should you do if your lot matches?

Contact your pharmacist or prescribing clinician and ask what to do next. Ask whether to keep taking the medicine while a replacement is arranged. Follow any return or disposal instructions your pharmacy provides. Do not stop a prescribed blood pressure medicine without first talking to your doctor or pharmacist — stopping suddenly can carry its own risks, and the FDA notes that patients can generally continue using a medicine in a Class II recall unless the company or the agency directs otherwise.

How is this different from other recent recalls?

Not every recall means contamination. This one is a quality failure in how the tablet dissolves, not a reported contamination finding. It is also narrow: 3,744 bottles in two lots, rather than every bottle of this medicine on the market. That is why the lot number — not just the medicine name — is the deciding detail.

Frequently asked questions

Is brand-name Tribenzor recalled? No. The FDA listing covers only the two Macleods generic lots above.

Does a Class II recall mean the medicine is dangerous? Class II is the FDA's middle severity tier. It means temporary or reversible health consequences are possible, while the probability of serious harm is remote. It is not a reason to change your routine without professional guidance.

What if I already finished a bottle from one of these lots? Talk to your pharmacist or prescriber about it, and mention any concerns about how well your blood pressure has been controlled. You can also report a medication-quality problem through the FDA MedWatch program or by calling 800-FDA-1088.

Where can I verify this myself? Search the FDA Enforcement Reports for recall number D-0077-2027, or check the lot number and NDC on your bottle against the details above.

Key Takeaway

Check the lot number, not just the medicine name: only Macleods lots 12251163A and 12251163B (3,744 bottles, expiring May 31, 2027) are recalled, and your pharmacist is the right first call if yours matches.

Sources: FDA Enforcement Report, recall D-0077-2027, classified October 26, 2026; AARP, “Blood Pressure Drug Recall: Check These Lots,” November 3, 2026; Becker's Hospital Review, November 2026, citing the FDA enforcement report.

---

This post was created with the help of AI tools and reviewed for accuracy against the sources cited above. It is general information only, not medical advice. For decisions about your own medicine, please talk to your doctor or pharmacist.